Larotinib drug profile

Larotrectinib is an innovative targeted therapy drug that is a tyrosine kinase inhibitor. What is unique about it is that it specifically targets tumors with NTRK gene fusions, which can be detected in a variety of cancers, including soft tissue sarcoma, infantile fibroma, lung cancer, etc.

NTRKgene fusion leads to abnormal activation ofNTRKkinase, which in turn promotes abnormal proliferation and survival signaling of tumor cells and promotes the development of tumors. Larotrectinib interferes with these abnormal signaling pathways by inhibiting the activity of NTRK kinase, thereby inhibiting tumor growth.

Clinical trials have shown that patients with NTRK gene fusions have achieved significant results after receiving larotrectinib treatment, showing tumor shrinkage, stopping progression or even complete disappearance. This makes larotrectinib a treatment option with significant individualized efficacy.

Larotinib is generally an oral drug, and the specific dosage and medication regimen need to be determined by the doctor based on the specific conditions of the patient. During use, patients need to be regularly monitored by doctors and the treatment plan adjusted to ensure the best treatment effect.

Larotrectinib has been launched in China and has not yet been included in medical insurance. Since it has not been launched in China for a long time, it may be difficult to purchase it in hospitals. For specific conditions, it is recommended to consult the local hospital pharmacy. In foreign markets, larotinib has two options: original drug and generic drug. Original drugs include the German version, the American version, the European version and the Hong Kong version, and the price is about 10,000 to 20,000 yuan. In comparison, generic drugs are much cheaper. There are Lao and Bangladeshi versions of generic drugs, and the price is around two to three thousand. It is worth noting that the ingredients of original drugs and generic drugs are basically the same.